| Mrs Patricia J Wilson, MD | |
|
4021 Balmoral Dr Sw, Huntsville, AL 35801-6403 | |
| (256) 539-2741 | |
| (256) 539-2775 |
| Full Name | Mrs Patricia J Wilson |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 30 Years |
| Location | 4021 Balmoral Dr Sw, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083692842 | NPI | - | NPPES |
| 51077860 | Other | AL | BCBS OF AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 21559 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Associates Pa | 2961425483 | 5 |
News Archive
Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent.
Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.
Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders.
Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.
The monitoring and treatment of eye diseases that may cause blindness has taken a big leap forward, thanks to a new imaging technique that takes high quality colour photographs of the whole retina.
› Verified 1 days ago
| Entity Name | Dermatology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972562213 PECOS PAC ID: 2961425483 Enrollment ID: O20060111000419 |
News Archive
Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent.
Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.
Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders.
Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.
The monitoring and treatment of eye diseases that may cause blindness has taken a big leap forward, thanks to a new imaging technique that takes high quality colour photographs of the whole retina.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Patricia J Wilson, MD 4021 Balmoral Dr Sw, Huntsville, AL 35801-6403 Ph: (256) 539-2741 | Mrs Patricia J Wilson, MD 4021 Balmoral Dr Sw, Huntsville, AL 35801-6403 Ph: (256) 539-2741 |
News Archive
Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent.
Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.
Both schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders.
Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.
The monitoring and treatment of eye diseases that may cause blindness has taken a big leap forward, thanks to a new imaging technique that takes high quality colour photographs of the whole retina.
› Verified 1 days ago
Dr. Ruth Yates, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 520 Madison St Se, Suite C, Huntsville, AL 35801 Phone: 256-536-4401 Fax: 256-536-3153 | |
Dr. Sharon Foster Gardepe, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 201 Sivley Rd Sw, Ste 510, Huntsville, AL 35801 Phone: 256-536-0992 | |
John M Evans, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2045 Cecil Ashburn Dr Se Ste 201, Huntsville, AL 35802 Phone: 256-925-3376 | |
Mrs. Emily Claire Jones, CRNP Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4810 Whitesport Cir Sw Ste 110, Huntsville, AL 35801 Phone: 256-715-5300 Fax: 866-222-8535 | |
Mr. Lon F Raby Jr., MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4021 Balmoral Dr Sw, Huntsville, AL 35801 Phone: 256-539-2741 Fax: 256-539-2775 | |
Melinda Birchmore Musick, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 410 Sivley Road Sw, Huntsville, AL 35801 Phone: 256-536-3738 Fax: 256-536-3737 |